{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:54:43Z","timestamp":1764341683984,"version":"3.46.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100208"],"award-info":[{"award-number":["82100208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"publisher","award":["CSTB2022-NSCQ-MSX0348"],"award-info":[{"award-number":["CSTB2022-NSCQ-MSX0348"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diffuse large B-cell lymphoma (DLBCL) is one of the most common and lethal B-cell malignancies worldwide, with high relapse rate after standard treatment, and the relapsed cases are often difficult to treat. Ubiquitination has a pivotal role in cellular protein homeostasis and tumorigenic deubiquitinases (DUBs) stabilize oncoproteins during carcinogenesis. In this study, we have identified USP13 as one of the abnormally-overexpressed and stage-related DUBs in DLBCL critical to disease pathogenesis. Employing LC-MS\/MS, Ran GTPase was characterized as potential substrate of USP13, with the interaction between Ran and USP13 modeled by Alphafold3. USP13 co-overexpressed, co-localized and correlated with Ran at protein level in DLBCL patient samples and cell lines. Pharmacological inhibition and genetic manipulation of USP13 modulated Ran protein stability and K11-linked ubiquitination level of Ran. By RNA-seq, pharmacological inhibition of USP13 via Spautin-1 treatment in DLBCL revealed downstream targets in NF-\u03baB and Notch pathways. Suggested by the DRESIS Database, NF-\u03baB and Notch signaling cascades are key to the resistance of Doxorubicin (Dox) and cyclophosphamide (CTX) within the standard R-CHOP regimen of DLBCL hinting benefits of combining Spautin-1 with Dox or CTX. Further in-vitro and in-vivo experiments confirmed Spautin-1 synergized with Dox or CTX to initiate ferroptosis in DLBCL with few toxicities to main organs by mediating ROS, GSH, MDA and ultimately LPO. Altogether, these results demonstrate USP13 deubiquitinates Ran in DLBCL, and Spautin-1 well synergizes with Dox or CTX to initiate ferroptosis. Combinational treatment with Spautin-1 and Dox or CTX may represent an effective approach and therapeutic hope to combat with DLBCL.<\/jats:p>","DOI":"10.1038\/s41419-025-08207-6","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:49:46Z","timestamp":1764341386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["USP13 dictates Ran turnover and vulnerability to ferroptosis in diffuse large B cell lymphoma (DLBCL)"],"prefix":"10.1038","volume":"16","author":[{"given":"Xuan","family":"Qiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingmeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanhao","family":"Diao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zailin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9304-9207","authenticated-orcid":false,"given":"Boheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"8207_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720\u20131748.","journal-title":"Leukemia"},{"key":"8207_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u2013511.","journal-title":"Nature"},{"key":"8207_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459:717\u2013721.","journal-title":"Nature"},{"key":"8207_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/leu.2017.251","volume":"32","author":"K Karube","year":"2018","unstructured":"Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32:675\u2013684.","journal-title":"Leukemia"},{"key":"8207_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379\u2013391.","journal-title":"Lancet Oncol"},{"key":"8207_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649\u2013662.","journal-title":"Lancet Oncol"},{"key":"8207_CR7","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","volume":"2","author":"C Keane","year":"2015","unstructured":"Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, et al. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol. 2015;2:e445\u2013455.","journal-title":"Lancet Haematol"},{"key":"8207_CR8","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","volume":"31","author":"P Armand","year":"2013","unstructured":"Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199\u20134206.","journal-title":"J Clin Oncol"},{"key":"8207_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216978","volume":"594","author":"B Li","year":"2024","unstructured":"Li B, Adam Eichhorn PJ, Chng WJ. Targeting the ubiquitin pathway in lymphoid malignancies. Cancer Lett. 2024;594:216978.","journal-title":"Cancer Lett"},{"key":"8207_CR10","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41388-023-02739-x","volume":"42","author":"C Ma","year":"2023","unstructured":"Ma C, Wang D, Tian Z, Gao W, Zang Y, Qian L, et al. USP13 deubiquitinates and stabilizes cyclin D1 to promote gastric cancer cell cycle progression and cell proliferation. Oncogene. 2023;42:2249\u20132262.","journal-title":"Oncogene"},{"key":"8207_CR11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119854119","volume":"119","author":"H Xie","year":"2022","unstructured":"Xie H, Zhou J, Liu X, Xu Y, Hepperla AJ, Simon JM, et al. USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer. Proc Natl Acad Sci USA. 2022;119:e2119854119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8207_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01892-x","volume":"22","author":"J Kwon","year":"2023","unstructured":"Kwon J, Zhang J, Mok B, Allsup S, Kim C, Toretsky J, et al. USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity. Mol Cancer. 2023;22:204.","journal-title":"Mol Cancer"},{"key":"8207_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02693-9","volume":"9","author":"S Zhang","year":"2018","unstructured":"Zhang S, Zhang M, Jing Y, Yin X, Ma P, Zhang Z, et al. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 2018;9:215.","journal-title":"Nat Commun"},{"key":"8207_CR14","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/ncb2874","volume":"15","author":"J Zhang","year":"2013","unstructured":"Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S, et al. Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol. 2013;15:1486\u20131494.","journal-title":"Nat Cell Biol"},{"key":"8207_CR15","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/s41388-021-01679-8","volume":"40","author":"EL Morgan","year":"2021","unstructured":"Morgan EL, Patterson MR, Barba-Moreno D, Scarth JA, Wilson A, Macdonald A. The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer. Oncogene. 2021;40:2112\u20132129.","journal-title":"Oncogene"},{"key":"8207_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899987","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Lin W, Li R, Cheng H, Sun S, Shao F, et al. The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer. Front Oncol. 2022;12:899987.","journal-title":"Front Oncol"},{"key":"8207_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381\u2013396.","journal-title":"Nat Rev Cancer"},{"key":"8207_CR18","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u2013282.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8207_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01606-6","volume":"15","author":"B Li","year":"2023","unstructured":"Li B, Zhou Q, Wan Q, Qiao X, Chen S, Zhou J, et al. EZH2 K63-polyubiquitination affecting migration in extranodal natural killer\/T-cell lymphoma. Clin Epigenetics. 2023;15:187.","journal-title":"Clin Epigenetics"},{"key":"8207_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07185-y","volume":"9","author":"B Liu","year":"2018","unstructured":"Liu B, Jiang S, Li M, Xiong X, Zhu M, Li D, et al. Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN. Nat Commun. 2018;9:4770.","journal-title":"Nat Commun"},{"key":"8207_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1084\/jem.20151673","volume":"214","author":"X Fang","year":"2017","unstructured":"Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang K, et al. Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. J Exp Med. 2017;214:245\u2013267.","journal-title":"J Exp Med"},{"key":"8207_CR22","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013w102.","journal-title":"Nucleic Acids Res"},{"key":"8207_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493\u2013500.","journal-title":"Nature"},{"key":"8207_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/cdd.2015.106","volume":"23","author":"J Wang","year":"2016","unstructured":"Wang J, Zhang Y, Hou J, Qian X, Zhang H, Zhang Z, et al. Ube2s regulates Sox2 stability and mouse ES cell maintenance. Cell Death Differ. 2016;23:393\u2013404.","journal-title":"Cell Death Differ"},{"key":"8207_CR25","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cell.2014.03.037","volume":"157","author":"HJ Meyer","year":"2014","unstructured":"Meyer HJ, Rape M. Enhanced protein degradation by branched ubiquitin chains. Cell. 2014;157:910\u2013921.","journal-title":"Cell"},{"key":"8207_CR26","doi-asserted-by":"publisher","first-page":"D1263","DOI":"10.1093\/nar\/gkac812","volume":"51","author":"X Sun","year":"2023","unstructured":"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, et al. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023;51:D1263\u2013d1275.","journal-title":"Nucleic Acids Res"},{"key":"8207_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18:280\u2013296.","journal-title":"Nat Rev Clin Oncol"},{"key":"8207_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fcell.2020.00345","volume":"8","author":"Z Boudhraa","year":"2020","unstructured":"Boudhraa Z, Carmona E, Provencher D, Mes-Masson AM. Ran GTPase: A Key Player in Tumor Progression and Metastasis. Front Cell Dev Biol. 2020;8:345.","journal-title":"Front Cell Dev Biol"},{"key":"8207_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41586-024-07060-5","volume":"627","author":"LH Ngo","year":"2024","unstructured":"Ngo LH, Bert AG, Dredge BK, Williams T, Murphy V, Li W, et al. Nuclear export of circular RNA. Nature. 2024;627:212\u2013220.","journal-title":"Nature"},{"key":"8207_CR30","doi-asserted-by":"publisher","first-page":"23589","DOI":"10.1074\/jbc.M115.660118","volume":"290","author":"V Sakin","year":"2015","unstructured":"Sakin V, Richter SM, Hsiao HH, Urlaub H, Melchior F. Sumoylation of the GTPase Ran by the RanBP2 SUMO E3 Ligase Complex. J Biol Chem. 2015;290:23589\u201323602.","journal-title":"J Biol Chem"},{"key":"8207_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-022-00355-5","volume":"17","author":"Y Lu","year":"2022","unstructured":"Lu Y, Meng Q, Bai L, Wang R, Sun Y, Li J, et al. LINC00858 stabilizes RAN expression and promotes metastasis of gastric cancer. Biol Direct. 2022;17:41.","journal-title":"Biol Direct"},{"key":"8207_CR32","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2019","unstructured":"Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394:2271\u20132281.","journal-title":"Lancet"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08207-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08207-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08207-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:49:47Z","timestamp":1764341387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08207-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8207"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08207-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"870"}}